A practical reference on Cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-10. Anything still debated is marked as such rather than presented as settled.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
=== Outer membrane and surface antigens === The of T. pallidum has several features that have made it historically difficult to research. These include details such as its fragility. The treponemal outer membrane (OM) proteins are key factors for the bacterium's pathogenesis, persistence, and immune evasion strategies. Treponema's reputation as a "stealth pathogen" is primarily due to this unique (OM) structure, which serves to evade immune detection. The outer membrane of Treponema pallidum contains a strikingly low concentration of transmembrane proteins, approximately 100-fold lower than other gram-negative bacteria or other spirochetes. This protects the cells from antibodies attacking it, hence they exhibit a "puzzling lack of antigenicity". The genome also revealed a bundle of 12 proteins and some putative hemolysins are potential virulence factors of T. pallidum. One protein, TprK, appears to constantly mutate to avoid immune response from its host.
Lajos Kisfaludy (30 August 1924 in Gemer, Czechoslovakia − 30 October 1988 in Budapest, Hungary) was a Hungarian chemical engineer, a corresponding member of the Hungarian Academy of Sciences. He is renowned for his research in the field of peptide synthesis and medicinal chemistry. From 1943, he studied at the Budapest University of Technology and graduated in 1948 as a chemical engineer. Until 1956, he taught at the Department of Organic Chemistry of the university. In 1956, he started to work for the Kőbánya Pharmaceutical Factory in Budapest as director and research professor of the synthesis laboratory, a position that he held from 1958 until his death. His main research was in the field of medicinal chemistry. He introduced new methods and protecting groups into the process of peptide synthesis. He contributed to the chemical synthesis of human hormones such as oxytocin and adrenocorticotropic hormone. As a result of his experiments, nearly 80 medicines were synthesized and introduced to the market (including Cavinton, Seduxen and Suprastin). He was a corresponding (1982) member of the Hungarian Academy of Sciences.
Granulation tissue is new connective tissue and microscopic blood vessels that form on the surfaces of a wound during the healing process. Granulation tissue typically grows from the base of a wound and is able to fill wounds of almost any size. Examples of granulation tissue can be seen in pyogenic granulomas and pulp polyps. Its histological appearance is characterized by proliferation of fibroblasts and thin-walled, delicate capillaries (angiogenesis), and infiltrated inflammatory cells in a loose extracellular matrix.
=== Local === Topical hemostatic agents have been gaining popularity for use in emergency bleeding control, especially in military medicine. They are available in three forms –as a granular powder poured on wounds, as a styptic pencil and embedded in a dressing.
Sources: en.wikipedia.org
=== Venom === Rattlesnake venom is hemotoxic, destroying tissue, causing necrosis and coagulopathy (disrupted blood clotting). In the U.S., the tiger rattlesnake (C. tigris) and some varieties of the Mojave rattlesnake (C. scutulatus) also have a presynaptic neurotoxic venom component known as Mojave type A toxin, which can cause severe paralysis. However, most North American rattlesnakes are not neurotoxic. Although it has a comparatively low venom yield, the venom toxicity of C. tigris is considered to be among the highest of all rattlesnake venoms, and among the highest of all snakes in the Western Hemisphere based on LD50 studies conducted on laboratory mice. C. scutulatus is also widely regarded as producing one of the most toxic snake venoms in the Americas, based on LD50 studies in laboratory mice. Rattlesnake venom is a mixture of five to fifteen enzymes, various metal ions, biogenic amines, lipids, free amino acids, proteins, and polypeptides. More specifically, there are three main families of toxins in rattlesnakes: phospholipases A2 (PLA2s), snake venom metalloproteinases (SVMPs), and snake venom serine proteinases (SVSPs). It contains components meant to immobilize and disable the prey, as well as digestive enzymes, which break down tissue to prepare for later ingestion. The venom is very stable, and retains its toxicity for many years in storage. Snake venom, in general, has a complex and ongoing evolutionary process, and rattlesnake venom is no different. The primary mechanisms of evolution are both gene duplication and gene loss events.
As a sign of the expanding commercial ties between the two regions (and Han and Tibetan peoples in particular), a special exhibition was held in Chengdu, so that Sichuanese may see and come into contact with Xikang products. In order to levy taxes from the region, Liu also established a Finance Ministry. Historians and analysts have debated over the effectiveness of these measures. Yang Zhonghua, writing in 1941, praised them as a relatively proactive policy; however, it has been argued by Xie Benzao that Liu's plans, though ambitious on paper, were limited by the realities of war and mostly for the purpose of resource extraction. Another road-building project of Liu Wenhui, constructed in the late 1920s from Yazhou to Chengdu, was known by locals mainly for the ruthlessness of its methods. Despite these projects, Xikang was mostly seen as a rear location distant from the conflicts in Sichuan. Liu encouraged students from Sichuan to take part in "border construction" in Xikang. In September 1929, he set up a newsletter, Bianzheng (邊政), dedicated to frontier administration. The issues of the Bianzheng promoted Sun Yat-sen's Three Principles and advertised Xikang as an attractive region for Chinese settlement, teeming with resources but nonetheless coveted by British imperialists. Propaganda plays published in the newsletter, which can be seen as the official policy of Liu Wenhui's government, exhorted youths to settle and develop the Xikang frontier, despite hardships, and thwart the imperialist plans of Tibet and Britain.
=== Information technology === The last decade has seen a proliferation of information technology use in the planning and conduct of clinical trials. Clinical trial management systems are often used by research sponsors or CROs to help plan and manage the operational aspects of a clinical trial, particularly with respect to investigational sites. Advanced analytics for identifying researchers and research sites with expertise in a given area utilize public and private information about ongoing research. Web-based electronic data capture (EDC) and clinical data management systems are used in a majority of clinical trials to collect case report data from sites, manage its quality and prepare it for analysis. Interactive voice response systems are used by sites to register the enrollment of patients using a phone and to allocate patients to a particular treatment arm (although phones are being increasingly replaced with web-based (IWRS) tools which are sometimes part of the EDC system). While patient-reported outcome were often paper based in the past, measurements are increasingly being collected using web portals or hand-held ePRO (or eDiary) devices, sometimes wireless. Statistical software is used to analyze the collected data and prepare them for regulatory submission. Access to many of these applications are increasingly aggregated in web-based clinical trial portals.
Sources: en.wikipedia.org
=== 20th century === By the early 20th century, when Robert Falcon Scott made his first expedition to the Antarctic (1901–1904), the prevailing theory was that scurvy was caused by "ptomaine poisoning", particularly in tinned meat. However, Scott discovered that a diet of fresh meat from Antarctic seals cured scurvy before any fatalities occurred. But while he saw fresh meat as a cure for scurvy, he remained confused about its underlying causes. In 1907, an animal model that would eventually help to isolate and identify the "antiscorbutic factor" was discovered. Axel Holst and Theodor Frølich, two Norwegian physicians studying shipboard beriberi contracted by ship's crews in the Norwegian Fishing Fleet, wanted a small test mammal to substitute for the pigeons then used in beriberi research. They fed guinea pigs their test diet of grains and flour, which had earlier produced beriberi in their pigeons, and were surprised when classic scurvy resulted instead. This was a serendipitous choice of animal. Until that time, scurvy had not been observed in any organism apart from humans and had been considered an exclusively human disease. Certain birds, mammals, and fish are susceptible to scurvy, but pigeons are unaffected since they can synthesize ascorbic acid internally. Holst and Frølich found they could cure scurvy in guinea pigs with the addition of various fresh foods and extracts.
Curium-244 alpha decays to 240Pu, but it also absorbs neutrons, hence a small amount of heavier curium isotopes. Of those, 247Cm and 248Cm are popular in scientific research due to their long half-lives. But the production rate of 247Cm in thermal neutron reactors is low because it is prone to fission due to thermal neutrons. Synthesis of 250Cm by neutron capture is unlikely due to the short half-life of the intermediate 249Cm (64 min), which β− decays to the berkelium isotope 249Bk.
Deep learning uses several layers of neurons between the network's inputs and outputs. The multiple layers can progressively extract higher-level features from the raw input. For example, in image processing, lower layers may identify edges, while higher layers may identify the concepts relevant to a human such as digits, letters, or faces. Deep learning has been used to improve the performance of programs in subfields of artificial intelligence including computer vision, speech recognition, natural language processing, image classification and others. Deep neural networks and backpropagation had been in development since 1950. Starting in 2012, the speed of deep learning was increased one hundred-fold by switching to GPUs, and there were enormous amounts of data available on the internet (called at the time "big data") as well as curated datasets used for benchmark testing, such as ImageNet. Usage of deep learning increased in 2012–2015 due to these improvements. In 2025, Geoffrey Hinton said that, until the 2010s, "We couldn't do anything very impressive because we didn’t have enough data and we didn't have enough computation."
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.